Aripiprazole-Sertraline Combination

How it works

Dosage & preparation

Risks & contraindications

Highlighted claims

• The ASCEnD medication guide suggests maximum doses of aripiprazole 10 mg/day and sertraline 150 mg/day. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• Sertraline was chosen for safety, pharmacokinetics, limited psychotropic interactions, tolerability, and lack of cardiac arrhythmia risk. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• Aripiprazole was selected because its pharmacological profile may improve antidepressant response while reducing manic switch risk. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• Lower-dose aripiprazole use is associated with symptom reduction and may reduce akathisia risk. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol
• Low-dose aripiprazole may amplify response to sertraline through dopamine and serotonin modulation. — Open-label randomised controlled trial of aripiprazole/sertraline combination in comparison with quetiapine for the clinical and cost-effectiveness of treatment of bipolar depression (the ASCEnD study): study protocol